PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Erregierre SPA	07/29/2010

RECEIVING PARTY DATA

Name:	Intercept Pharmaceuticals, Inc.	
Street Address:	18 Desbrosses Street	
City:	New York	
State/Country:	NEW YORK	
Postal Code:	10013	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11914559

CORRESPONDENCE DATA

Fax Number: (617)542-2241

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: (617) 542-6000

Email: jfoley@mintz.com

Correspondent Name: Ivor R. Elrifi

Address Line 1: One Financial Center

Address Line 2: Mintz, Levin

Address Line 4: Boston, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER: 35147-601N01US

NAME OF SUBMITTER: Jennifer L. Loebach

Total Attachments: 2

source=35147-601N01US Assignment#page1.tif source=35147-601N01US Assignment#page2.tif

OP \$40.00 119

PATENT REEL: 025202 FRAME: 0921

EXHIBIT B

ASSIGNMENT

WHEREAS Erregierre SPA has previously assigned to Intercept Pharmaceuticals a 50% undivided right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any country to the above inventions, discoveries and applications described and claimed in PCT/EP2006/062446, filed May 16, 2006, all as set forth in the attached Patent Assignment Agreement executed on December 12, 2008 (attached hereto), now Erregierre SPA wishes to assign the remaining 50% of its undivided right, title and interest to the inventions, discoveries and applications described and claimed in PCT/EP2006/062446, as set forth below:

We, Erregierre SPA ("ASSIGNOR"), Via Francesco Baracca 19, 24060 San Paola D'Argon, ITALY, the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, confirm that we do hereby assign, sell and transfer to Intercept Pharmaceuticals ("ASSIGNEE"), with offices at 18 Desbrosses Street, New York, NY 10013:

(1) the entirety of ASSIGNOR's remaining 50% undivided right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in:

PCT/EP2006/062446, filed May 16, 2006

- (2) the entirety of ASSIGNOR's remaining 50% undivided right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and
- (3) the entirety of ASSIGNOR's remaining 50% undivided right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

We hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

We further covenant that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR.

Exhibit B-1

PATENT

REEL: 025202 FRAME: 0922

Signed for on behalf of Erregierre SPA	
By: Messauche Gargar	<u>L</u>
Title: MCE PRESIDENT	_ Date: 29 July
County of 17AU	<u> </u>
	Witnessed By: MATTEO GHILARDI
	Address: VIA IV NOVEMBRE 16, BERGAMO, ITAL
	Date: <u>JULY 29, 2010</u>
Signed for on behalf of Intercept Pharmaceuti	cals Inc

Date: <u>July 29 2010</u>

Exhibit B-2

4971146v.1

RECORDED: 10/27/2010

PATENT

REEL: 025202 FRAME: 0923